Single-dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer.
Peter HoskinAna RojasPeter OstlerRobert HughesRoberto AlonziGerry Lowe
Published in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2024)
Long-term outcome data show reduced but not statistically significant difference in PSA control, and no difference in overall survival, between SD-HDR-BT and 2 or 3 fractions of HDR-BT.